Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maria Belen Picatoste Botija"'
Autor:
Rodolfo San Antonio, Maria Belen Picatoste Botija, Juan J. Badimon, Carlos G. Santos-Gallego, Shin Watanabe, Roger J. Hajjar, Valentin Fuster, Mohammad Urooj Zafar, Juan Antonio Requena Ibanez, Kiyotake Ishikawa
Publikováno v:
Journal of the American College of Cardiology. 71:A1852
SGLT2 inhibitor empagliflozin (EMPA) reduces CV death by 40% and heart failure by 35%. Of note, there is no decrease in myocardial infarction or stroke. In fact, there is a numerical increase in stroke rate in the EMPA-treated group (a non-significan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d727e0f9c8be67099a5f8b348403a71
https://doi.org/10.1016/s0735-1097(18)32393-3
https://doi.org/10.1016/s0735-1097(18)32393-3
Autor:
Carlos G. Santos-Gallego, Rodolfo San Antonio, Juan J. Badimon, Valentin Fuster, Maria Belen Picatoste Botija, Roger J. Hajjar, Angel Sanz Salvo, Shin Watanabe, Juan Antonio Requena Ibanez, Kiyotake Ishikawa
Publikováno v:
Journal of the American College of Cardiology. 71:A674
Mechanisms behind heart failure reduction with SGLT2 inhibitor empagliflozin (EMPA) in clinical trials remain unclear. Given that EMPA causes mild, persistent hyperketonemia, we hypothesized that cardiac benefits of EMPA are due to a shift in myocard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be5bd4b21694536d513935fdda37c584
https://doi.org/10.1016/s0735-1097(18)31215-4
https://doi.org/10.1016/s0735-1097(18)31215-4